LM 007 - LaNova Medicines Limited
Alternative Names: LM-007 - LaNova Medicines LimitedLatest Information Update: 23 Oct 2022
Price :
$50 *
At a glance
- Originator LaNova Medicines Limited
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Oct 2022 LM 007 - LaNova Medicines Limited is available for licensing as of 04 Oct 2022. https://www.lanovamedicines.com/foreign-cooperation?tp=2
- 04 Oct 2022 Preclinical trials in Solid tumours in China (Parenteral) (LaNova Medicines pipeline, October 2022)